Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + epirubicin + carboplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of paclitaxel, epirubicin, and carboplatin. This regimen is primarily used for treating metastatic or recurrent endometrial carcinoma and has also been studied in advanced bladder cancer and metastatic breast cancer. The combination works through multiple mechanisms: paclitaxel stabilizes microtubules, epirubicin intercalates DNA and inhibits topoisomerase II, and carboplatin forms DNA crosslinks. The regimen typically requires G-CSF support to manage neutropenia.
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on paclitaxel + epirubicin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + epirubicin + carboplatin.